In the last years much attention has been given to the implementation of the so-called targeted drugs. One of the targets of tumours is the vasculature and this has led to the development of anti-angiogenic drugs. In lung cancer the use of these drugs has resulted in both positive and negative studies. In this paper the pros and cons are presented. We hope that this information will help the physician in making a proper treatment choice.
University College London Hospital and UCL Cancer Institute, London, Department of Oncology, University College Hospital, London, UK. sm.lee@uclh.nhs.uk
